For patients with advanced HCC, preserved liver function (Child–Pugh A), and Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, they recommend combinations including at least one PD-1 or PD-L1 inhibitor, provided there are no contraindications (Level of Evidence 1, strong recommendation, strong consensus). Here, PDCD1 is linked to hepatocellular carcinoma.